Edition:
India

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

13.40USD
9:20pm IST
Change (% chg)

$0.20 (+1.52%)
Prev Close
$13.20
Open
$13.15
Day's High
$13.45
Day's Low
$12.90
Volume
26,600
Avg. Vol
199,375
52-wk High
$19.90
52-wk Low
$11.85

Latest Key Developments (Source: Significant Developments)

Momenta Pharma says Q3 loss per share $0.44
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc -:Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 revenue $24.1 million versus $29.1 million.Q3 revenue view $30.6 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.44.Q3 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.Momenta Pharmaceuticals - co and Mylan are targeting a first regulatory submission for clinical development of M710 by early 2018​.Momenta Pharmaceuticals - ‍updated non-GAAP operating expense guidance of about $200 million - $210 million for 2017 and $43 million - $53 million for Q4 of 2017​.Momenta Pharmaceuticals Inc - ‍expects to recognize $50 million upfront payment from CSL as revenue in Q4 of 2017​.Momenta Pharmaceuticals Inc - ‍estimates that collaborative reimbursement revenues will be approximately $0 - $2 million in Q4 of 2017​.  Full Article

Momenta And Mylan report initial results from phase 1 clinical trial for M834
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc :Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept).Mylan NV - ‍M834, a proposed biosimilar of Orencia (Abatacept), did not meet its primary pharmacokinetic (PK) endpoints in phase 1 study​.Mylan NV - ‍Momenta And Co continue to gather and analyze data to inform next steps for M834 program ​.  Full Article

Mmenta Pharmaceuticals to regain global development and commercialization rights to M923
Tuesday, 27 Sep 2016 

Momenta Pharmaceuticals Inc. : Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire . Agreement to terminate 12 months following notice; Shire will continue to be obligated to fund M923 program till termination . Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire .Co expects top-line results of current phase 3 trial of M923 in late 2016.  Full Article

Momenta Pharmaceuticals reports Q2 loss per share $0.31
Thursday, 4 Aug 2016 

Momenta Pharmaceuticals Inc : Q2 loss per share $0.31 . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S .Q2 revenue $26.4 million versus I/B/E/S view $22.9 million.  Full Article

Momenta Pharmaceuticals Inc announces worldwide collaboration with Mylan NV
Friday, 8 Jan 2016 

Momenta Pharmaceuticals Inc:Announces worldwide collaboration with Mylan NV to jointly develop and commercialize six biosimilar products.Under agreement, Mylan will make an upfront cash payment of $45 million and up to $200 million in contingent milestone payments to Momenta, with each company sharing equally in the costs and profits with respect to the products.Companies will be jointly responsible for product development and Mylan will lead worldwide commercialization efforts.  Full Article

BRIEF-Momenta Pharma says Q3 loss per share $0.44

* Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update